Related Experiment Videos
Costs of coronary restenosis (Lovastatin Restenosis Trial)
S P Gilbert1, W S Weintraub, J D Talley
1Department of Medicine, Emory University School Medicine, Atlanta, Georgia, USA.
Insights
Restenosis after coronary interventions significantly increases healthcare costs and resource use. Reducing restenosis can improve treatment effectiveness and lower long-term expenses, enhancing cost-effectiveness.
Area of Science:
- Cardiovascular medicine
- Health economics
Background:
- Restenosis is a significant complication following coronary interventions.
- Increased resource utilization and costs are associated with restenosis.
Purpose of the Study:
- To analyze the economic impact of restenosis.
- To highlight the importance of reducing restenosis for cost-effectiveness.
Main Methods:
- Analysis of data from the Lovastatin Restenosis Trial.
- Evaluation of resource utilization and costs related to restenosis.
Main Results:
- Restenosis was demonstrated to increase resource utilization and associated costs.
- The study provides insights into the economic burden of restenosis.
Conclusions:
- Decreasing restenosis is crucial for improving the efficacy of coronary interventions.
- Reducing restenosis can lead to lower follow-up costs and enhanced cost-effectiveness.
Abstract:
Within the Lovastatin Restenosis Trial, restenosis has been clearly shown to increase resource utilization and costs. While it is not possible to generalize these results to other patient populations, it is clear that successful efforts to decrease restenosis will certainly improve efficacy while decreasing follow-up costs and increasing the cost-effectiveness of intervention in the coronaries.